This trial is evaluating whether Tirofiban Hydrochloride will improve 2 primary outcomes and 2 secondary outcomes in patients with Ischemia. Measurement will happen over the course of Up to 2 weeks post enrollment.
This trial requires 60 total participants across 2 different treatment groups
This trial involves 2 different treatments. Tirofiban Hydrochloride is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
Ischemia results from reduced blood flow to a part of the body or when the arteries supplying that part are blocked. It can occur temporarily as a result of a heart attack, or permanently. A blocked artery can be caused by a blood clot, an abnormality of the artery wall, or a tumor.\nKey Points\n- Ischemia, or lack of oxygen to tissue, can result from either inadequate blood flow to an area, poor blood perfusion to an area, or when the arteries supplying this area and the blood flowing through it are blocked.
In a cardiac arrest, there are 3 crucial and overlapping steps of brain stem ischemia: ischemia, hypoxia, and hypoperfusion. The signs of ischemia: asymmetric brain stem tone, abnormal level or pattern of eye movement and pupils, as well as absent or low blood pressure are the main manifestations. An important finding in the prehospital period is the need of monitoring the level of hemoglobin, carboxyhemoglobin, lactate, and base deficit of blood. We suggested that an S1 heart sound is indispensable in prehospital emergency situations.
The number of angina symptoms and symptoms associated with myocardial ischemia vary a great deal among US populations. Because of the variability of angina symptoms and the relatively low percentage of cases with significant ischemia, we believe it is important and meaningful to report the number of cases of major ischemia and their associated symptoms. It is also important to compare the results of different populations to estimate the true number of cases of ischemia per year. We estimated the annual incidence of severe ischemia in the United States and determined the incidence of symptoms associated with ischemia in seven major population samples. Although the incidence is greatest in those most vulnerable to ischemia, its influence on total population-wide burden can be substantial.
Many people have coronary artery disease and are taking medications to alter the heart rate. Cardiology tests on stable patients may detect heart attack or other heart disease. Physicians recommend a low-fat diet when considering low-cholesterol diets or fibrates. Medications that control the blood pressure may be used to prevent and treat heart disease. Patients with high cholesterol may need medications to lower the blood cholesterol.
Ischemia is not a common complication of dental anesthesia. It is estimated to be about 7% with dental surgery and 1.5% with endodontic surgery. Dental surgery without anesthesia carries a higher risk of ischemia than dental anesthesia with no regional anesthesia.
Ischemia (euglycemic hyperinsulinemia) does not promote angiogenesis, and is not a therapeutic target. Thus, therapies such as hyperbaric oxygen may help people who have no symptoms for years.
According to [Power (ischemic-conditioned cardiomyopathy)], the most recent research findings include [improved heart conditioning in mice with heart failure by the use of [cyclic GMP analogs] and [mPTP opening as a therapy in heart disease. You can visit Power (ischemic-conditioned cardiomyopathy) for clinical trials, which includes trials in the US and Canada. power also has clinical trials in Europe and Australia. power also keeps clinical trial updates in the UK. you can [power (UK Clinical Trials Gateway) (https://www.trialregister.ac.
This is the first comprehensive discussion of recent developments in the development of tirofiban hydrochloride in therapeutic usage. The drug market for tirofiban hydrochloride, marketed as renoStat, has expanded rapidly since its introduction on the market in 2005. A large number of studies have been registered in several countries.
In a recent study, findings demonstrated for the first time that tirofiban had the potential to improve QOL of patients with moderate to severe angina symptoms.
The study results indicate that the use of tirofiban in patients undergoing off-pump coronary artery surgery should be continued if it decreases the risk of myocardial infarction.
Recent findings of this study provide a new insight into the pathogenesis of post-heart attack IHD. More importantly, our findings will help physicians with the diagnosis and treatment of the patients admitted for IHD.
Tirofiban hydrochloride does not represent a good alternative in patients with the indication of an acute MI in whom thrombus is detected by CT, or in patients with a moderate to severe unstable angina pectoris who receive aspirin alone or in combination with thrombolytic therapy.